0001551152-26-000008
SEC filingAbbVie Inc. reported FY 2025 net revenues of $61.16 billion, generating operating earnings of $15.07 billion and net earnings attributable to AbbVie Inc. of $4.23 billion. The company's gross profit was $42.96 billion, resulting in a gross margin of 70.2%. Operating margin stood at 24.6%. Cash flow from operating activities was strong at $19.03 billion, while free cash flow was $17.82 billion. The balance sheet shows total assets of $133.96 billion, with significant long-term debt of $58.94 billion and a total equity deficit of -$3.23 billion. Basic and diluted earnings per share were $2.00. The company paid $11.66 billion in dividends and repurchased $980 million in treasury stock during the year.
AbbVie Inc. reported FY 2025 financial results with net revenues of $61.16 billion. The company achieved operating earnings of $15.07 billion and net earnings attributable to AbbVie Inc. of $4.23 billion. Basic and diluted earnings per share were $2.00 based on weighted-average basic shares outstanding of 1.77 billion. The cost structure included cost of products sold of $18.20 billion, selling, general and administrative expenses of $14.01 billion, research and development expenses of $9.10 billion, and acquired IPR&D and milestones of $5.02 billion. Other operating income contributed $241 million. Interest expense, net was $2.63 billion, net foreign exchange loss was $58 million, and other expense, net was $5.79 billion. Income tax expense was $2.36 billion.
No segment breakdown, geographic mix, or specific growth drivers are disclosed in the provided financial data. The analysis is limited to the consolidated financial statements showing total net revenues of $61.16 billion for FY 2025.
Gross profit was $42.96 billion, calculated as net revenues of $61.16 billion minus cost of products sold of $18.20 billion, resulting in a gross margin of 70.2%. Operating margin was 24.6%, calculated as operating earnings of $15.07 billion divided by net revenues of $61.16 billion. The company's cost structure shows significant investment in research and development ($9.10 billion) and acquired IPR&D and milestones ($5.02 billion), along with substantial selling, general and administrative expenses ($14.01 billion).
Cash flow from operating activities was $19.03 billion, driven by net earnings of $4.23 billion plus significant non-cash adjustments including amortization of intangible assets ($7.38 billion), change in fair value of contingent consideration liabilities ($6.50 billion), and stock-based compensation ($955 million). Free cash flow was $17.82 billion, calculated as operating cash flow of $19.03 billion minus capital expenditures of $1.21 billion. The balance sheet shows total assets of $133.96 billion, including cash and equivalents of $5.23 billion, accounts receivable of $12.59 billion, inventories of $4.95 billion, intangible assets of $52.64 billion, and goodwill of $35.64 billion. Total liabilities were $137.19 billion, including current liabilities of $43.29 billion and long-term debt of $58.94 billion. Total equity showed a deficit of -$3.23 billion.
No management guidance, strategic priorities, or specific risk factors are disclosed in the provided financial data. The analysis is limited to the historical financial results for FY 2025 as presented in the financial statements.